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Clinical Medicine and Surgery, Federico II UnivAbstract Background and aim: Obesity is increasing worldwide and is related to undesirable
cardiovascular outcomes. Epicardial fat (EF), the heart visceral fat depot, increases with obesity
and correlates with cardiovascular risk. SIRT1, an enzyme regulating metabolic circuits linked
with obesity, has a cardioprotective effect and is a predictor of cardiovascular events. We aimed
to assess the relationship of EF thickness (EFT) with circulating SIRT1 in patients with obesity.
Methods and results: Sixty-two patients affected by obesity and 23 lean controls were studied.
Plasma SIRT1 concentration was determined by enzyme-linked immunosorbent assay (ELISA).
EFT was measured by echocardiography. Body mass index (BMI), waist circumference, heart rate
(HR), blood pressure, and laboratory findings (fasting glucose, insulin, HbA1c, cholesterol, and
triglycerides) were assessed.
SIRT1 was significantly lower (P Z 0.002) and EFT was higher (P < 0.0001) in patients with
obesity compared with lean controls. SIRT1 showed a negative correlation with EFT and HR in
the obesity group (r Z 0.350, P Z 0.005; r Z 0.303, P Z 0.008, respectively). After
adjustment for obesity-correlated variables, multiple linear regression analysis showed that
EFT remained the best correlate of SIRT1 (b Z 0.352, P Z 0.016).
Conclusions: Circulating SIRT1 correlates with the visceral fat content of the heart. Serum SIRT1
levels might provide additional information for risk assessment of coronary artery disease in
patients with obesity.
ª 2016 The Italian Society of Diabetology, the Italian Society for the Study of Atherosclerosis, the
Italian Society of Human Nutrition, and the Department of Clinical Medicine and Surgery,
Federico II University. Published by Elsevier B.V. All rights reserved.Introduction
Sirtuins (SIRTs) regulate many metabolic adaptations in
obesity [1]. SIRT1, the most intensely studied sirtuin family
member, regulates the expression of adipokines, represses
the activity of factors required for maturation of fat cells,
alters mitochondrial capacity, regulates insulin secretion
and sensitivity, and modulates plasma glucose levels [1]. In970721; fax: þ39 6 4461450.
o.com (S. Mariani).
etology, the Italian Society for the Study
ersity. Published by Elsevier B.V. All righaddition, SIRT1 prevents diet-induced obesity and
associated non-alcoholic fatty liver disease [2], a condition
of ectopic fat accumulation accompanied by a decrease in
SIRT1 expression at both circulating [3] and visceral
adipose tissue (VAT) levels [4]. In line with these
observations, the weight loss induces a SIRT1 concentra-
tion increase in plasma [5], adipose tissue, and liver [6] in
patients with obesity. Overall, SIRT1 is found to be pro-
tective against endothelial dysfunction, atherothrombosis,
myocardial infarction [2], and cardiovascular diseases in
general. Indeed, by controlling the cardiac metabolic gene
expression through modulation of the peroxisomeof Atherosclerosis, the Italian Society of Human Nutrition, and the Department of
ts reserved.
1034 S. Mariani et al.proliferator activated receptor a (PPARa) pathway, SIRT1
protects the heart from hypertrophy, metabolic dysregu-
lation, and inflammation [7,2].
Epicardial fat (EF), the adipose tissue of the heart, is a
VAT. It covers 80% of the heart’s surface and, because of its
anatomical contiguity with the heart, locally modulates
the functions of myocardium and coronary arteries
through a paracrine cross talk [8e10]. EF has potential
cardioprotective effects that can be exerted mechanically,
thermogenically, and throughout the local secretion of
adipokines [8]. However, excess EF carries a great predic-
tion of mortality [11]. Specifically, EF thickness (EFT) is
associated with premature coronary artery disease [12]
and obstructive sleep apnea [13]. EFT increases in predia-
betic patients, regardless of fasting plasma glucose and
HbA1c [14], and in patients with type 2 diabetes mellitus
and obesity [15], representing a diagnostic criterion for
patients with metabolic syndrome [16]. It is also inversely
correlated with endothelial function [17]. In this study, we
focused on the association of circulating SIRT1 levels with
the visceral fat of the heart, represented by EF, in patients
affected by obesity.
Methods
Study population
We studied 85 subjects, 62 affected by obesity (19 men and
43 women) and 23 healthy lean controls (7 men and 19
women). Study participants were recruited from among
subjects referred to the High Specialization Center for the
Care of Obesity at the Department of Experimental Medi-
cine, “Sapienza” University of Rome. Inclusion criteria
comprised age (18e65 years), race (Caucasian ethnicity),
BMI  30 kg/m2 for obese patients, and BMI  18.5
and  24.9 kg/m2 for controls. As exclusion criteria, we
considered corticosteroids for systemic use, any medica-
tion, or any clinical condition potentially affecting body
weight, autoimmune diseases, renal failure, heart failure,
type 1 diabetes, and malignant disease during the last 5
years.
The average age was 39.58  12.27 years (range 18e65
years) for subjects with obesity and 41.69  10.84 years
(range 22e59 years) for controls. Subjects affected by
obesity and previously diagnosed with diabetes mellitus,
dyslipidemia, or hypertension were receiving glucose-,
lipid-, and BP-lowering agents for each of these conditions.
All subjects were enrolled after written informed consent.
The study was approved by the local ethical committee
and was concordant with the Helsinki Declaration.
Measurements
The patients underwent complete medical examination
and anthropometric measurements (body weight, height,
waist circumference (WC)). Body weight was measured by
Tanita BWB-800A digital medical scale (Tanita Corpora-
tion, Arlington Heights, IL, USA). Body mass index (BMI)
was calculated as body weight (kg) divided by heightsquared (m2). After overnight fasting, serum SIRT1, glyce-
mia, insulin, total cholesterol, low-density lipoprotein-
cholesterol (LDL-C), high-density lipoprotein-cholesterol
(HDL-C), and triglycerides were determined. Heart rate
(HR) and systolic and diastolic blood pressure (mmHg)
measured by a mercury sphygmomanometer (Riva-Rocci
System, ERKA, Chemnitz, Germany) were recorded. EFT
(mm) was measured by ultrasound.SIRT1 assays
The plasma SIRT1 concentration was determined by a
monoclonal antibody-based enzyme-linked immunosor-
bent assay (ELISA) method, using a commercially available
human SIRT1 ELISA kit (MyBioSource, Cod. GDMBS
705558) as previously described [3]. Microtiter plates were
coated with equal amount of primary mouse anti-human
SIRT1 monoclonal IgG. Hundred-microliter standard and
serum samples were pipetted in each well and the pro-
tocol was followed by using secondary avidin conjugated
with horseradish peroxidase. The formation of horseradish
peroxidase was measured at 405 nm using an ELISA reader
(Quanta Biotech, UK). Seven different concentrations of
purified SIRT1 (0.15, 0.312, 0.625, 1.25, 2.5, 5.0, and 10 ng/
mL) were used to plot a standard curve. The inter- and
intra-assay coefficients of variation were 4% and 6%,
respectively, with a detection limit of 0.1 ng/mL.Epicardial fat thickness measurements
EFT was measured through a validated echocardio-
graphic procedure [18]. Participants underwent high-
resolution M-B-mode transthoracic echocardiography
using a 2.5-MHz probe and spectral Doppler exam of the
common carotid artery using a 7.5-MHz probe (Esaote
MyLab40, Esaote Europe B.V., the Netherlands). The EFT
was identified as the echo-free space between the outer
wall of the myocardium and the visceral layer of the
pericardium, and its thickness was measured perpen-
dicularly on the free wall of the right ventricle (RV) at
the end systole in three cardiac cycles. The average value
of three cardiac cycles from each echocardiographic view
was considered. All echocardiograms were recorded by
the same experienced operator, who was blinded to the
other study data.Statistical analysis
Results were expressed as mean  SD. The degree of as-
sociation between variables was calculated using Spear-
man’s nonparametric correlation. A p-value of <0.05 was
considered statistically significant. Sex- and age-adjusted
multivariate regression analyses were realized in subjects
with obesity to verify the associations among SIRT1 and
relevant variables (EFT, HR, BMI, WC, and HbA1c). Data
were analyzed with the use of STATISTICA software,
version 6.1 (StatSoft, Inc., Tulsa, OK, USA).
Figure 1 Correlation between circulating SIRT1 and epicardial fat
thickness in people with obesity. Correlation coefficient (r) and level of
significance (P) are provided.
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The demographic, anthropometric, and clinical character-
istics of the patients are shown in Table 1. The patients
with obesity (BMI, mean  SD 41.82  7.67 kg/m2) showed
echocardiographic evidence of increase in EFT (P < 0.0001)
and significantly lower SIRT1 circulating levels (PZ 0.002)
compared with normal-weight subjects. The WC was
constantly 80 cm in females and 94 cm in males with
obesity. The group of healthy lean controls (BMI,
mean  SD 23.26  1.60 kg/m2) had no ultrasound evi-
dence of increase in EFT. The total cholesterol (PZ 0.045),
LDL-C (P Z 0.040), systolic BP (P Z 0.041), diastolic BP
(P Z 0.011), and insulin (P Z 0.020) levels were signifi-
cantly lower in the population of lean controls (Table 1).
The correlation between SIRT1 and the other variables
was analyzed using the Spearman correlation coefficient
test. In the population with obesity, SIRT1 was negatively
correlated with EFT (r Z 0.350; P Z 0.005) (see Fig. 1)
and HR (r Z 0.303; P Z 0.008). On the contrary, SIRT1
did not correlate with BMI (P Z 0.326), WC (P Z 0.263),
FPG (P Z 0.415), and the other parameters tested. A ten-
dency to a negative correlation with HbA1c was also seen
(rZ 0.216; PZ 0.062). In the healthy lean control group,
SIRT1 did not correlate with any of the parameters
measured (data not shown).
Sex- and age-adjusted multivariate regression analyses
for the associations between SIRT1 and other relevant
variables (EFT, HR, BMI, WC, and HbA1c) in patients with
obesity are shown in Table 2. The analysis revealed a sig-
nificant negative correlation between the levels of SIRT
and the EFT, which remained the best independent
correlate of SIRT1 (R Z 0.429, R2 Z 0.184, b Z 0.352,
P Z 0.016).Table 1 Demographic, anthropometric, and clinical characteristics
of the patients.
Variables Obese subjects
(n Z 62)
Normal weight
(n Z 23)
P
Age (years) 39.58  12.27 41.69  10.84 0.439
SIRT1 (ng/ml) 1.36  1.31 2.27  1.13 0.002
Weight (kg) 116.17  24.36 65.09  7.07 <0.0001
BMI (kg/m2) 41.82  7.67 23.26  1.60 <0.0001
WC (cm) 126.21  14.71 78.80  11.91 <0.0001
Epicardial fat (mm) 8.49  0.87 6.97  0.57 <0.0001
Heart rate (bpm) 73.58  8.53 74.30  6.44 0.695
FPG (mg/100 ml) 100.57  21.42 98.65  16.15 0.677
Insulin (mcUI/ml) 16.48  14.04 9.88  3.95 0.020
HbA1c (%) 5.05  0.62 4.77  0.92 0.089
Systolic BP (mmHg) 127.36  14.51 120.57  14.09 0.041
Diastolic BP (mmHg) 79.34  10.46 73.57  7.43 0.011
Total-C (mg/100 ml) 197.69  33.45 183.42  21.92 0.045
LDL-C (mg/100 ml) 120.68  28.17 107.66  25.71 0.040
HDL-C (mg/100 ml) 48.66  12.90 49.30  15.22 0.835
Triglycerides
(mg/100 ml)
132.81  82.86 108.36  50.61 0.160
Abbreviations: SIRT1, sirtuin1; BMI, body mass index; WC, waist
circumference; FPG, fasting plasma glucose; HbA1c, glycated he-
moglobin; BP, blood pressure; HDL-C, high-density lipoprotein-
cholesterol; LDL-C, Low-density lipoprotein-cholesterol. Values are
expressed as means  SD.According to previous studies [19], a correlation be-
tween EFT and both BMI (r Z 0.617, P < 0.0001) and WC
(r Z 0.640, P < 0.0001) was found.Discussion
VAT, including the EF surrounding the heart, shows many
histological and functional peculiarities. VAT contains a
large number of inflammatory cells and expresses several
hormone receptors, and its adipocytes are metabolically
active and sensitive to lipolysis. The increased amount of
VAT carries, in general, a great prediction of mortality [11]
and EF, which substantially mirrors visceral adiposity
rather than general obesity, has been correlated with car-
diovascular risk factors [8,13,14]. EFT increases in obese
patients. It is a useful parameter in the assessment of pa-
tients with obesity and other cardio-metabolic diseases
[17]. Due to its proximity to the heart, by secreting pro-
inflammatory cytokines EF exerts direct local metabolic
effects. This condition promotes local cardiovascular dis-
eases and contributes, together with other ectopic fat de-
pots, tometabolic derangements and diabetesmellitus [20].
SIRT1, a (NADþ)-dependent enzyme, is significantly
involved in the metabolic adaptations observed in obesityTable 2 Age- and sex-adjusted multivariate regression analysis of
SIRT1.
Independent variables b p
EFT (mm) 0.352 0.016
HR (bpm) 0.133 0.316
BMI (kg/m2) 0.134 0.557
WC (cm) 0.096 0.689
HbA1c (%) 0.157 0.220
Abbreviations: SIRT1, sirtuin1; EFT, epicardial fat thickness; HR,
heart rate; BMI, body mass index; WC, waist circumference; HbA1c,
glycated hemoglobin. EFT, HR, BMI, WC, and HbA1c were entered in
the multiple regression analysis to predict SIRT1, the dependent
variable. EFT was the best independent correlate of SIRT1 in pa-
tients with obesity.
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obesity and higher SIRT1 expression after weight loss, both
in tissues [6] and in bloodstream [5], suggesting that SIRT1
is downregulated in obesity. The awareness of the role of
SIRT1 against metabolic derangements such as diabetes,
dyslipidemia, and liver steatosis has been increasing [21,
[22]. This role is further highlighted by the observation of a
low SIRT1 pathway expression in subcutaneous adipose
tissue from a population of BMI-discordant monozygotic
twins [23] affected by obesity, inflammation, insulin
resistance, and impaired mitochondrial protein homeo-
stasis. This datum, besides suggesting a strong relationship
of reduced SIRT1 expression with indices of metabolic
dysfunction, indicates a close relationship between SIRT1
and acquired obesity independent of the genetic back-
ground [23].
To date, substantial evidence suggests a role of SIRT1 in
cardioprotection [2]. The relevance of SIRT1 as a cardiac
gene regulator is well established, and low SIRT1 expres-
sion in the context of cardiovascular disease has been re-
ported [7]. Furthermore, SIRT1 shows a significant
contribution in oxidant and antioxidant balance in heart
failure [24] and, via activating eNOS, its overexpression
protects against myocardial ischemiaereperfusion injury
in diabetic rats, representing a promising therapeutic
target for cardiac complications in diabetics [25]. Finally,
the SIRT1 gene KO leads to cardiac malformations and
increased perinatal mortality in mice [26].
In this study, we evaluated the relationship between
SIRT1 and the visceral fat depot of the heart. We found that
EFT is a strong negative correlate of the circulating SIRT1 in
individuals affected by obesity. This behavior closely re-
sembles that of other bioactive compounds produced by EF
with reported cardioprotective effects, both in vivo and
in vitro. For example, the increase in EFT is accompanied
by a reduced expression of adiponectin [27], decreased
circulating adiponectin levels in genetic and diet-induced
murine models of obesity, and downregulated EF adreno-
medullin gene and protein expression in subjects with
coronary artery disease [28]. Thus, SIRT1, analogously to
bioactive adipokines originating from EF, shows a corre-
lation with cardio-metabolic status and amount of EF.
Accordingly, EF revealed a unique transcriptome that
shows profound modifications in patients with coronary
artery disease [29], and among the differentially expressed
genes in human EF to identify molecules associated with
cardiovascular diseases, SIRT1 was represented [30].
Consistent with previous studies [3,5], we did not find a
relationship between circulating SIRT1 and BMI or WC,
although an association among EFT, BMI, and WC was
seen. This observation confirms that the increase in BMI
and WC may not reflect a reduction in SIRT1, which is a
distinctive trait of individuals mostly with visceral obesity,
nor may it be representative of the excess visceral fat
depot responsible for the severity of cardio-metabolic
complications of obesity. Furthermore, since regional fat
depots may be of greater importance than overall
adiposity, traditional anthropometric measures should be
viewed with caution. Our finding highlights the poorrelationship between SIRT1 and the classic measures of
adiposity. Indeed, analogously to the recent observation of
a negative association between SIRT1 and liver steatosis
[3], a condition of ectopic fat accumulation, we found a
significant correlation between SIRT1 and EF, the ectopic
visceral fat depot of the heart whose major drive is not
obesity but excessive visceral fat accumulation [8]. Thus,
SIRT1 is preferentially associated with visceral fat rather
than with obesity per se. From this point of view, SIRT1
could be elevated to the rank of marker associated with
the predisposition to accumulate fat viscerally. It is note-
worthy that in normal-weight patients, who had higher
SIRT1 concentration and lower EFT than patients with
obesity did, we observed that the correlation between
SIRT1 and EFT was lacking. Interestingly, myocardial
dysfunction seems to be related to scarce metabolic con-
trol rather than to fat mass or BMI [31]. Previous data have
suggested that patients with obesity yet metabolically
healthy carry a reduced risk of cardiovascular disease or
mortality than patients with normal weight yet metabol-
ically unhealthy [32]. However, the definition of metabol-
ically healthy obesity is established using BMI, an
improper index of adiposity. Therefore, SIRT1 measure-
ment could help in stratifying cardiovascular disease risk
and identifying metabolically healthy or unhealthy obese
phenotypes. The exact mechanisms involved in the inverse
relationship between circulating SIRT1 and EFT reported
here are unknown. Mounting evidence shows that SIRT
transcription and/or protein levels are persistently
reduced in specific tissue during chronic inflammation.
Examples include fat deposits in obesity with inflamma-
tion, brain in Alzheimer’s disease, and arterial inflamma-
tion in atherosclerosis [33]. Thus, a working hypothesis,
which deserves further investigation, is that excess EF in
patients with visceral obesity displays a pro-inflammatory
phenotype; an oxidative stress environment is created,
mainly due to a state of chronic inflammation prone to
secreting tumor necrosis factor alpha (TNF-a), interleukin
(IL)-6, and inducible nitric oxide synthase (iNOS), with
heightened inflammation associated with low SIRT1 and
expansion of adipose tissue.
Although EF may be a major source of circulating SIRT1,
because of the widespread distribution of the potential
tissue sources of SIRT1 [21], additional sources of circu-
lating SIRT1, besides EF, cannot be ruled out.
Unexpectedly, SIRT1 correlated with the HR in patients
with obesity. The exact mechanism for such an association
is unclear, and this aspect of the study deserves further
investigation. However, the diversity of SIRT1 targets may
explain the complexity of its function in different tissues,
including the cardiac electric tissue. Consistently,
increased SIRT1 expression is found in the right auricle
tissues of patients with atrial fibrillation (AF) [34]. More-
over, EF is significantly thicker in individuals with chronic
AF than in those with paroxysmal AF, suggesting that long-
term exposure to EF excess might relate to chronic AF [35].
Finally, recent data showed that PDE5 inhibitor treat-
ment in humans reduces EF and upregulates SIRT1 in both
serum and subcutaneous fat, opening novel therapeutic
Circulating SIRT1 and epicardial fat in obesity 1037strategies for EF remodeling and regulation of SIRT1 to
promote healthier fat deposits [36].
Conclusion
In conclusion, the findings of this study suggest that in
people with obesity, SIRT1, a metabolically crucial enzyme,
is inversely and independently associated with EFT, but no
relationship between circulating SIRT1 and BMI or WC was
seen. A large body of evidences suggests a role of SIRT1 as
a predictor of cardiovascular events, and our present data
seem to go in the same direction. Overall, the down-
regulation of SIRT1 expression observed at the circulating
level and in visceral and subcutaneous adipose tissues of
people with obesity [37], paralleled by the increase in
epicardial VAT, may contribute to the cardio-metabolic
abnormalities associated with obesity. This field will be
further investigated in the light of the disposability of
SIRT1 mimetics/activators able to increase SIRT1 activities.
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